Ticker Details
Wave Life Sciences Ltd. Ordinary Shares WAVE Life Sciences Ltd is a preclinical therapeutics developer in Singapore. Its pipeline of drugs is intended to cure rare genetic disorders such as Huntington, duchenne muscular dystrophy (DMD) and inflammatory bowel disease.
IPO Date:	November 11, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.04B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.50 | 3.64%
Avg Daily Range (30 D):	$0.15 | 2.51%
Avg Daily Range (90 D):	$0.16 | 2.54%

Institutional Daily Volume
Avg Daily Volume:	.78M
Avg Daily Volume (30 D):	2.41M
Avg Daily Volume (90 D):	2.96M

Trade Size
Avg Trade Size (Sh.):	112
Avg Trade Size (Sh.) (30 D):	106
Avg Trade Size (Sh.) (90 D):	118

Institutional Trades
Total Institutional Trades:	1,715
Avg Institutional Trade:	$1.73M
Avg Institutional Trade (30 D):	$1.91M
Avg Institutional Trade (90 D):	$2.23M
Avg Institutional Trade Volume:	.17M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.28M
Avg Closing Trade (30 D):	$2.05M
Avg Closing Trade (90 D):	$2.77M
Avg Closing Volume:	242.29K

News

May 14, 2026 @ 5:00 PM Oligonucleotides Clinical Trial Drug Development P... Source: Delveinsight

Feb 2, 2026 @ 7:16 PM Wave Life Sciences Reclaims Rare Disease Drug From... Source: Vandana Singh

Dec 11, 2025 @ 7:01 AM Golden Cross Alert: 3 Stocks With Major Upside Pot... Source: Chris Markoch

Dec 10, 2025 @ 2:50 AM Wave Life Sciences Prices Upsized $350 Million Pub... Source: Wave Life Sciences

Dec 10, 2025 @ 12:19 AM Why Wave Life Sciences Stock Crushed it Again Toda... Source: Eric Volkman

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.08	$-.34	$-.13
Diluted EPS	$-1.08	$-.34	$-.13
Revenue	$65.37M	$2.27M	$38.25M
Gross Profit
Net Income / Loss	$-202.47M	$-69.36M	$-26.09M
Operating Income / Loss	$-217.92M	$-73.8M	$-31.3M
Cost of Revenue
Net Cash Flow	$159.53M	$-176.71M	$-57.46M
PE Ratio